These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 18313854)

  • 1. Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma.
    Verma S; Younus J; Stys-Norman D; Haynes AE; Blackstein M;
    Cancer Treat Rev; 2008 Jun; 34(4):339-47. PubMed ID: 18313854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
    Lorigan P; Verweij J; Papai Z; Rodenhuis S; Le Cesne A; Leahy MG; Radford JA; Van Glabbeke MM; Kirkpatrick A; Hogendoorn PC; Blay JY;
    J Clin Oncol; 2007 Jul; 25(21):3144-50. PubMed ID: 17634494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Santoro A; Tursz T; Mouridsen H; Verweij J; Steward W; Somers R; Buesa J; Casali P; Spooner D; Rankin E
    J Clin Oncol; 1995 Jul; 13(7):1537-45. PubMed ID: 7602342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
    Antman K; Crowley J; Balcerzak SP; Rivkin SE; Weiss GR; Elias A; Natale RB; Cooper RM; Barlogie B; Trump DL
    J Clin Oncol; 1993 Jul; 11(7):1276-85. PubMed ID: 8315425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ifosfamide-based combination chemotherapy in advanced soft-tissue sarcoma: a practice guideline.
    Verma S; Younus J; Stys-Norman D; Haynes AE; Blackstein M
    Curr Oncol; 2007 Aug; 14(4):144-8. PubMed ID: 17710206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma.
    Fayette J; Penel N; Chevreau C; Blay JY; Cupissol D; Thyss A; Guillemet C; Rios M; Rolland F; Fargeot P; Bay JO; Mathoulin-Pelissier S; Coindre JM; Bui-Nguyen B
    Invest New Drugs; 2009 Oct; 27(5):482-9. PubMed ID: 19148579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy of advanced sarcomas of bone and soft tissue.
    Antman KH
    Semin Oncol; 1992 Dec; 19(6 Suppl 12):13-20. PubMed ID: 1485169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
    Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT;
    Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-intensive chemotherapy with growth factor or autologous bone marrow/stem cell transplant support in first-line treatment of advanced or metastatic adult soft tissue sarcoma: a systematic review.
    Verma S; Younus J; Stys-Norman D; Haynes AE; Blackstein M;
    Cancer; 2008 Mar; 112(6):1197-205. PubMed ID: 18224666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma.
    Pervaiz N; Colterjohn N; Farrokhyar F; Tozer R; Figueredo A; Ghert M
    Cancer; 2008 Aug; 113(3):573-81. PubMed ID: 18521899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy of advanced soft-tissue sarcomas.
    Antman KH; Elias AD
    Semin Surg Oncol; 1988; 4(1):53-8. PubMed ID: 3281212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment results obtained in metastatic soft-tissue sarcoma with a combination of doxorubicin and dacarbazine or doxorubicin and ifosfamide.
    Weh HJ; Agarwal K; Zornig C; Schwarz R; Dietel M; Hossfeld DK
    Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S189-93. PubMed ID: 8453696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of ifosfamide in combination with doxorubicin for the treatment of metastatic soft-tissue sarcoma. The Eastern Cooperative Oncology Group.
    Blum RH; Edmonson J; Ryan L; Pelletier L
    Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S238-40. PubMed ID: 8453706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
    Sleijfer S; Ouali M; van Glabbeke M; Krarup-Hansen A; Rodenhuis S; Le Cesne A; Hogendoorn PC; Verweij J; Blay JY
    Eur J Cancer; 2010 Jan; 46(1):72-83. PubMed ID: 19853437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group.
    Le Cesne A; Judson I; Crowther D; Rodenhuis S; Keizer HJ; Van Hoesel Q; Blay JY; Frisch J; Van Glabbeke M; Hermans C; Van Oosterom A; Tursz T; Verweij J
    J Clin Oncol; 2000 Jul; 18(14):2676-84. PubMed ID: 10894866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy.
    Elias A; Ryan L; Sulkes A; Collins J; Aisner J; Antman KH
    J Clin Oncol; 1989 Sep; 7(9):1208-16. PubMed ID: 2504890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Preliminary result of advanced soft tissue sarcoma treated by MAID regimen].
    Huang YH; Wen XP; Hu L
    Ai Zheng; 2002 Aug; 21(8):907-9. PubMed ID: 12478905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
    Edmonson JH; Ryan LM; Blum RH; Brooks JS; Shiraki M; Frytak S; Parkinson DR
    J Clin Oncol; 1993 Jul; 11(7):1269-75. PubMed ID: 8315424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity.
    Bui BN; Chevallier B; Chevreau C; Krakowski I; Peny AM; Thyss A; Maugard-Louboutin C; Cupissol D; Fargeot P; Bonichon F
    J Clin Oncol; 1995 Oct; 13(10):2629-36. PubMed ID: 7595717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Responses of 109 adult soft tissue sarcoma patients to chemotherapy].
    Qiu MZ; Xu F; Wang SS; Luo HY; Wang F; Li FH; Sun XF; Xu GC; Lin TY; Huang HQ; Jiang WQ; Guan ZZ; Xu RH
    Ai Zheng; 2007 Dec; 26(12):1344-9. PubMed ID: 18076798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.